WO2015144184A8 - Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer - Google Patents

Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer Download PDF

Info

Publication number
WO2015144184A8
WO2015144184A8 PCT/DK2015/050069 DK2015050069W WO2015144184A8 WO 2015144184 A8 WO2015144184 A8 WO 2015144184A8 DK 2015050069 W DK2015050069 W DK 2015050069W WO 2015144184 A8 WO2015144184 A8 WO 2015144184A8
Authority
WO
WIPO (PCT)
Prior art keywords
timp
treatment
biomarker
colorectal cancer
metastatic colorectal
Prior art date
Application number
PCT/DK2015/050069
Other languages
French (fr)
Other versions
WO2015144184A1 (en
Inventor
Nils Aage Brünner
José Moreira
Ib Jarle Christensen
Line Schmidt TARPGAARD
Per PFEIFFER
Original Assignee
University Of Copenhagen
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Copenhagen, Rigshospitalet filed Critical University Of Copenhagen
Publication of WO2015144184A1 publication Critical patent/WO2015144184A1/en
Publication of WO2015144184A8 publication Critical patent/WO2015144184A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention concerns the provision of biomarkers, in particular, TIMP-1 and RAS as biomarkers for the selection of patients in the treatment and prognosis of cancer, such as e.g. metastatic colorectal cancer (mCRC). The present invention also provides methods of patient selection, patient prognosis and methods of treatment of patients based on TIMP-1 levels in the blood, plasma or tumor tissue and the absence or presence of mutations in RAS, in particular KRAS, who are likely to benefit from treatment with an EGFR inhibitor alone or in combination with at least one chemotherapeutic agent. The present invention also provides for a method of treatment of m CRC in patients, which have been identified by the inventive method using the biomarker TIMP-1 and KRAS, who are likely to benefit from the treatment with the EGFR inhibitor cetuximab and at least one chemotherapeutic agent.
PCT/DK2015/050069 2014-03-26 2015-03-26 Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer WO2015144184A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400174 2014-03-26
DKPA201400174 2014-03-26

Publications (2)

Publication Number Publication Date
WO2015144184A1 WO2015144184A1 (en) 2015-10-01
WO2015144184A8 true WO2015144184A8 (en) 2015-10-29

Family

ID=52997162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2015/050069 WO2015144184A1 (en) 2014-03-26 2015-03-26 Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer

Country Status (1)

Country Link
WO (1) WO2015144184A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3385395T1 (en) 2015-08-17 2020-07-31 Kura Oncology, Inc. Methods of treating cancer patients with farnesyl transferase inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176773A1 (en) * 2009-06-19 2012-01-30 Merck Patent Gmbh Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations

Also Published As

Publication number Publication date
WO2015144184A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
CY1122642T1 (en) ANTI-B7-H1 AND ANTI-CTLA-4 ANTIBODIES FOR THE THERAPEUTIC TREATMENT OF NON-SMALL CELL LUNG CANCER
MX2017014381A (en) Therapeutic and diagnostic methods for cancer.
MX2017008421A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder.
EP3867410A4 (en) Methods for determining treatment for cancer patients
WO2016196298A8 (en) Therapeutic and diagnostic methods for cancer
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
WO2014151006A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
MX2016012285A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression.
EP3580560A4 (en) Methods for the detection and treatment of lung cancer
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
EA201692472A1 (en) CONNECTIONS FOR THE TREATMENT OF BRAIN CANCER
IL273782A (en) Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
MX2017014735A (en) Pd-l1 promoter methylation in cancer.
MX2016001854A (en) Compositions and method for treating complement-associated conditions.
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
EP3762493A4 (en) Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
EP3796933A4 (en) Methods for treating, preventing and detecting the prognosis of colorectal cancer
WO2015112705A3 (en) Therapeutic combinations for treating cancer
EP3444362A3 (en) Circulating mirnas as early detection marker and prognostic marker
EP3371211A4 (en) Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
EP3292218A4 (en) Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
MX2017014540A (en) Biomarkers for a combination therapy comprising lenvatinib and everolimus.
WO2015144184A8 (en) Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15717793

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 15717793

Country of ref document: EP

Kind code of ref document: A1